---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-25-000099"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:52:06.288676+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M

## Summary
- Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
- Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).
- Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.
- Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.
- Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025.

## SEC filing metadata
- accession: 0001161697-25-000099
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/0001161697-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-25-000099
- JSON: https://secwatch.observer/filing/0001161697-25-000099.json
- Plain text: https://secwatch.observer/filing/0001161697-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.